Opinion|Videos|December 7, 2023
Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma
The panel explains which BRAF/MEK inhibitor combination therapy they each tend to turn to when treating a patient with BRAF-mutated metastatic melanoma.
Advertisement
Advertisement
Related to this article
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer
3
FSHR-Directed CAR T-Cell Therapy Yields Instance of Stable Disease in Recurrent Ovarian Cancer
4
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
5